SMO and acute myeloid leukemia: After clinical trials for the use of previously approved SMO inhibitors in AML therapy failed, glasdegib (PF-04449913, Daurismo) in combination with low-dose cytarabine (LDAC) was the first SMO inhibitor to receive FDA approval for the treatment of AML at the end of 2018.